At the news
? BULLISHIMPACT 8/10 6-K filed Apr 17, 2026 at 15:30 ET
Evaxion A/S announced phase 2 trial data showing its AI-designed personalized cancer vaccine EVX-01 achieved an 86% success rate in triggering tumor-specific immune responses, a key validation of its AI-Immunology platform. The results, to be presented at AACR, also show durable immune responses and de novo T-cell activation, reinforcing the vaccine's therapeutic potential in advanced melanoma.
- 86% of vaccine targets in EVX-01 triggered a tumor-specific immune response, described as a record high
- Durable vaccine-specific immune responses observed over two years
- High de novo T-cell response rate (86%) indicates strong immune system activation
- Positive correlation between AI-prediction scores and immune response magnitude confirmed
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access